Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Massimo CristofanilliHope S RugoSeock-Ah ImDennis J SlamonNadia HarbeckIgor BondarenkoNorikazu MasudaMarco ColleoniAngela DeMicheleSherene LoiHiroji IwataBen O'LearyFabrice AndreSibylle LoiblEustratios BananisYuan LiuXin HuangSindy KimMaria Jose Lechuga FreanNicholas C TurnerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The clinically meaningful improvement in OS associated with palbociclib plus fulvestrant was maintained with >6 years of follow-up in patients with HR+/HER2- ABC, supporting palbociclib plus fulvestrant as a standard of care in these patients.